Nobilis Reo+IB+G+ND

Not authorised

- Newcastle disease virus, strain Clone 30, Inactivated
- Avian reovirus, strain 1733, Inactivated
- Avian reovirus, strain 2408, Inactivated
- Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
- Infectious bursal disease virus, strain D78, Inactivated

Product identification

Medicine name:
Nobilis Reo+IB+G+ND

Active substance:
Newcastle disease virus, strain Clone 30, Inactivated

Avian reovirus, strain 1733, Inactivated

Avian reovirus, strain 2408, Inactivated

Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated

Infectious bursal disease virus, strain D78, Inactivated

Target species:
Chicken

Route of administration:
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:

Newcastle disease virus, strain Clone 30, Inactivated
50.00 50% Protective Dose / 0.50 millilitre(s)

Avian reovirus, strain 1733, Inactivated
7.40 log2 enzyme-linked immunosorbent assay unit(s) / 0.50 millilitre(s)

Avian reovirus, strain 2408, Inactivated
7.40 log2 enzyme-linked immunosorbent assay unit(s) / 0.50 millilitre(s)

Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
6.00 log2 haemagglutination inhibiting unit(s) / 0.50 millilitre(s)

Infectious bursal disease virus, strain D78, Inactivated
14.50 log2 virus neutralising unit(s) / 0.50 millilitre(s)

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Chicken**
  - Meat and offal. 0 day
  - Egg. 0 day

Subcutaneous use:

- **Chicken**
  - Meat and offal. 0 day
  - Egg. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AA06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Surrendered

Authorised in:
Germany

Package description:
Available only in German
Available only in German

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet Deutschland GmbH

Marketing authorisation date:
24/10/1996

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
91a/94

Date of authorisation status change:
13/04/2023

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.